Ann: SCENESSE European Orphan Drug Designation for VP, page-15

Yep. Why make money now when you can make it later. The mantra of all successful companies.

is anyone aware of the phase 3 trial plans for VP? Best wait a bit longer to extend exclusivity or is it kept secret so not to help our competitors or maybe it would make it more difficult to negotiate with the regulators. Or maybe the market is so so tiny and the condition doesn’t effect QAL enough to justify an expensive treatment that it’s just not economic sense to pursue it.

i only know that after a decade of talking about it a single inconsequential trial has been completed and then we’ve heard nothing since.